HC Wainwright raises target for Genmab stock from USD 40 to USD 50

Published on 10/15/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genmab reported USD 4.24 billion in DARZALEX sales in the third quarter. The USD 1.16 billion revenue figure frames Genmab stock.

Royalty growth and analyst view

DARZALEX sales reached USD 4.24 billion in the third quarter of 2026, according to an October 13 report.
HC Wainwright raised its Genmab target from USD 40 to USD 50 on October 7, 2026.
Genmab is scheduled to report quarterly results on November 5, 2026.

Architektur-Render eines modernen Biotech-Firmengebäudes mit Glasfassade und Grünflächen — Genmab A/S moderner Biotech-Campus in Kopenhagen als architektonisches Render mit Glasfassade und Grünanlage, DK0010272202, Illustration mit AI erstellt.

HC Wainwright raised its Genmab price target from USD 40 to USD 50 on October 7, 2026, while maintaining a Buy rating, as MarketBeat reported. The move keeps Genmab's late-stage pipeline at the center of the investment case.

Royalty growth adds operating support

Genmab's royalty engine also delivered a fresh operating signal. Worldwide DARZALEX sales reached USD 4.24 billion in the third quarter of 2026, up from USD 3.67 billion in the third quarter of 2025, according to RTTNews. The product is marketed by Johnson and Johnson, with Genmab receiving royalty income through the companies' commercial partnership.

Genmab reported USD 1.16 billion in revenue and USD 303.00 million in net profit for the second quarter of 2026, compared with USD 924.81 million of revenue and USD 335.93 million of net profit in the year-earlier period, according to The Globe and Mail. Revenue expanded while profit declined, leaving pipeline execution and spending important to the valuation.

What does the target reset mean?

HC Wainwright's target increase from USD 40 to USD 50 was the latest in a series of bullish analyst actions. MarketBeat also cited Guggenheim's increase from USD 45 to USD 54 and described a consensus of one Strong Buy, nine Buys and three Holds on October 7, 2026. The target reset reflects expectations for Genmab's antibody portfolio, but it remains an analyst view rather than company guidance.

Three milestones frame Genmab

On October 3, 2026, Genmab reported a 45.90 percent confirmed response rate among 109 patients in the RAINFOL-01 trial of Rina-S, including five complete responses, according to AP News. On October 7, 2026, HC Wainwright set its USD 50 target after raising it from USD 40. On October 13, 2026, DARZALEX sales reached USD 4.24 billion for the third quarter.

Next reporting date is November 5

Genmab's next scheduled quarterly results are listed for November 5, 2026, according to TickerLandia. That date will give investors a fresh view of royalty income, operating costs and progress across the Rina-S program.

Pipeline and royalties shape the outlook

Genmab combines commercial royalty income with a broad antibody pipeline. The latest sequence of trial data, analyst targets and DARZALEX sales puts the balance between near-term cash generation and development spending at the center of the stock story.